BRPI0506679A - métodos de tratar osteoartrite com antagonistas de il-6 - Google Patents

métodos de tratar osteoartrite com antagonistas de il-6

Info

Publication number
BRPI0506679A
BRPI0506679A BRPI0506679-4A BRPI0506679A BRPI0506679A BR PI0506679 A BRPI0506679 A BR PI0506679A BR PI0506679 A BRPI0506679 A BR PI0506679A BR PI0506679 A BRPI0506679 A BR PI0506679A
Authority
BR
Brazil
Prior art keywords
antagonists
methods
treating osteoarthritis
osteoarthritis
treating
Prior art date
Application number
BRPI0506679-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Susan Elizabeth Bove
Kenneth Stanley Kilgore
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34885980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0506679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0506679A publication Critical patent/BRPI0506679A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0506679-4A 2004-02-11 2005-01-31 métodos de tratar osteoartrite com antagonistas de il-6 BRPI0506679A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54381404P 2004-02-11 2004-02-11
PCT/IB2005/000240 WO2005080429A2 (en) 2004-02-11 2005-01-31 Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies

Publications (1)

Publication Number Publication Date
BRPI0506679A true BRPI0506679A (pt) 2007-05-15

Family

ID=34885980

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506679-4A BRPI0506679A (pt) 2004-02-11 2005-01-31 métodos de tratar osteoartrite com antagonistas de il-6

Country Status (9)

Country Link
US (2) US20080145367A1 (https=)
EP (1) EP1715891B2 (https=)
JP (1) JP2008505054A (https=)
AT (1) ATE464908T1 (https=)
BR (1) BRPI0506679A (https=)
CA (1) CA2555688C (https=)
DE (1) DE602005020743D1 (https=)
ES (1) ES2341461T5 (https=)
WO (1) WO2005080429A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
JP2009092508A (ja) * 2007-10-09 2009-04-30 Norihiro Nishimoto リウマチ治療剤の効果の予測方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN102271705A (zh) 2008-12-22 2011-12-07 墨尔本大学 骨关节炎治疗
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010106812A1 (en) * 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
MX341578B (es) * 2011-02-08 2016-08-25 Abbvie Inc Tratamiento de la osteoartritis y del dolor.
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EP3194025A4 (en) * 2014-09-18 2018-05-23 Rush University Medical Center Methods for preventing or treating osteoarthritis
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
CA2991637C (en) 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
KR20200012823A (ko) 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3735421A4 (en) 2018-01-05 2021-09-22 Corvidia Therapeutics, Inc. METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2021067749A2 (en) * 2019-10-02 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for the treatment of osteoarthritis
EP4159236A4 (en) 2020-05-29 2024-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT52962A (en) * 1988-03-04 1990-09-28 Sandoz Ag Process for production of medical compositions eliminating bone-absorption and promoting forming of bones
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ES2384222T3 (es) * 1994-10-07 2012-07-02 Chugai Seiyaku Kabushiki Kaisha Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo
US5617790A (en) * 1995-05-31 1997-04-08 P.R. Graphics Limited Apparatus for producing flexographic printing plates
US20030202977A1 (en) * 1998-11-16 2003-10-30 New York University Treatment of osteoarthritis
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações

Also Published As

Publication number Publication date
EP1715891B1 (en) 2010-04-21
CA2555688A1 (en) 2005-09-01
US20100215654A1 (en) 2010-08-26
US20080145367A1 (en) 2008-06-19
DE602005020743D1 (de) 2010-06-02
WO2005080429A3 (en) 2006-02-23
JP2008505054A (ja) 2008-02-21
CA2555688C (en) 2011-11-08
EP1715891B2 (en) 2014-08-13
WO2005080429A2 (en) 2005-09-01
ATE464908T1 (de) 2010-05-15
ES2341461T5 (es) 2014-10-29
EP1715891A2 (en) 2006-11-02
ES2341461T3 (es) 2010-06-21

Similar Documents

Publication Publication Date Title
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
NL301145I2 (nl) Tirbanibulin
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
TW200626171A (en) Fixed dosing of HER antibodies
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA200870409A1 (ru) Антагонисты киназы pi3
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
TW200732349A (en) Anti-OX40L antibodies and methods using same
EA200802168A1 (ru) Гуманизированное антитело к с-kit
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
EA201171307A1 (ru) Антагонисты толл-подобного рецептора 3
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
ATE499138T1 (de) Implantierbare vorrichtung
DK1835912T3 (da) Substituerede benzimidazoler til behandling af histomoniasis
EA200501137A1 (ru) Способ и промежуточные соединения для получения оланзапина
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.